This is a news story, published by Yahoo, that relates primarily to Moderna news.
For more Moderna news, you can click here:
more Moderna newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
vaccine manufacturers Pfizer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Novavax vaccine news, COVID vaccine news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
vaccine optionVerywell Health
•80% Informative
Pfizer and Moderna , whose mRNA vaccines are easy to update, say their shots will target the KP.2 variant.
Novavax, which makes a protein-based vaccine, will not be able to update its formula.
An advisory committee to the CDC will determine who should actually get an updated COVID vaccine late next week .
VR Score
74
Informative language
68
Neutral language
72
Article tone
formal
Language
English
Language complexity
56
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
9
Source diversity
5
Affiliate links
no affiliate links